Report #2880653

Received Jan 5, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: NJ
Recovered: Unknown
Vaccinated: Oct 29, 2025
Onset: Oct 29, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	23E4B	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

patient that got the first dose of Shingrix 31-AUG-2023 and second dose on 29-OCT-2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) (batch number 23E4B, expiry date 05-JUN-2027) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix on 31-AUG-2023 with lot CR3S5 and expiry of 08 OCT 2024). On 29-OCT-2025, the patient received the 2nd dose of Shingrix. On 29-OCT-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient that got the first dose of Shingrix 31-AUG-2023 and second dose on 29-OCT-2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 02-JAN-2026 A pharmacist wanted to get recommendations for a patient that got the second dose late. The vaccine administration facility was the same as primary reporter.